Bladder & Urothelial Cancer Excellence Forum

Bladder & Urothelial Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Quiz

Quiz: After the use of platinum-based chemotherapy for DRD-biomarker positive patients with urothelial carcinoma, which drug was found to improve PFS according to a phase 2 trial?

10/21/2022

After the use of platinum-based chemotherapy in the first-line setting for DNA repair deficiency-biomarker positive patients with urothelial carcinoma, which drug was found to improve progression-free survival according to a phase 2 trial?

After the use of platinum-based...

10/21/2022

Oncology

Benjamin Miron, MD, Fox Chase Cancer Center

Videos

Immune Checkpoint Inhibitors Following Platinum Chemotherapy Regimens in Urothelial Carcinoma

10/17/2022

Benjamin Miron, MD, discusses a study comparing survival on single-agent immune checkpoint inhibitors in the second-line treatment setting, following either cisplatin or carboplatin, in patients with urothelial carcinoma.

Benjamin Miron, MD, discusses a...

10/17/2022

Oncology

Simon Crabb, PhD, MBBS, University of Southampton

Videos

Maintenance Rucaparib Following Chemotherapy for DNA Repair Deficiency Biomarker-Positive Urothelial Carcinoma

09/29/2022

Simon Crabb, PhD, MBBS, reviews results from a randomized, double-blind phase 2 trial of maintenance rucaparib following chemotherapy in DNA repair deficiency biomarker-positive patients with metastatic urothelial carcinoma.

Simon Crabb, PhD, MBBS, reviews...

09/29/2022

Oncology

Quiz

Enfortumab Vedotin Plus Pembrolizumab for Urothelial Cancer

09/27/2022

In an analysis of Cohort K from the EV-103 trial evaluating enfortumab vedotin plus pembrolizumab for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, did that the combination therapy have an objective...

In an analysis of Cohort K from...

09/27/2022

Oncology

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center

VIDEOS

Enfortumab Vedotin Plus Pembrolizumab Induces High Response Rates in Cisplatin-Ineligible Patients With Urothelial Cancer

09/20/2022

Allison Casey ;

Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.

Jonathan Rosenberg, MD, reviews...

09/20/2022

Oncology

Quiz

Quiz: Pembrolizumab Plus Sacituzumab Govitecan in Platinum-Refractory Metastatic Urothelial Cancer

07/21/2022

True or False: Combination pembrolizumab and sacituzumab govitecan demonstrated a clinical benefit among patients with platinum-refractory metastatic urothelial cancer.

True or False: Combination...

07/21/2022

Oncology

Petros Grivas, MD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab Yields Encouraging Response Rates in Metastatic Urothelial Cancer

06/22/2022

Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Petros Grivas, MD, shares...

06/22/2022

Oncology

Podcasts

Maintenance Therapy With Cabozantinib Shows No Significant Benefit vs Placebo for Metastatic Urothelial Carcinoma

06/21/2022

Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.

Robert Jones, MD, shares results...

06/21/2022

Oncology

Joseph Jacob, MD, SUNY Upstate University Hospital

Podcasts

Joseph Jacob, MD, Reviews SunRISe-1 Trial Progress in High-Risk, Non–Muscle-Invasive Bladder Cancer

03/02/2022

Dr Jacob highlights the progress of SunRISe-1: a phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non–muscle-invasive bladder cancer unresponsive to BCG who are ineligible for or...

Dr Jacob highlights the progress...

03/02/2022

Oncology

Bishoy Faltas, MD, Weill Cornell Medicine

Videos

Serial ctDNA Analysis Predicts Clinical Progression, Guides Precision Medicine in Advanced Urothelial Carcinoma

02/17/2022

Bishoy Faltas, MD, discusses targeted sequencing of circulating tumor DNA (ctDNA) to monitor changes in the variant allele frequencies of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma.

Bishoy Faltas, MD, discusses...

02/17/2022

Oncology

Recent News

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

News

Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer

05/01/2020

Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.

Switch maintenance pembrolizumab...

05/01/2020

Oncology

News

Enfortumab Vedotin Monotherapy Yields Durable Responses in Metastatic Urothelial Cancer

02/26/2020

Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.

Enfortumab vedotin monotherapy...

02/26/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology